Expertise in
18
conditions

Matthias Guckenberger

Josef Schneider Str. 11, 
Wuerzburg, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
18
conditions
Josef Schneider Str. 11, 
Wuerzburg, BY, DE 

Overview

Matthias Guckenberger practices practicing medicine in Wuerzburg, Germany.

Mr. Guckenberger is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Metastases, Prostatectomy, and Hepato-Pancreato-Biliary Surgery.

He is actively involved in clinical research, co-authoring 604 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Josef Schneider Str. 11, Wuerzburg, BY 97080, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
Enrollment Status: Recruiting
Publish Date: August 26, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Immune-modulatory Radiotherapy to Enhance the Effects of Neoadjuvant PD-L1 Blockade After Neoadjuvant Chemotherapy in Patients With Resectable Stage III(N2) Non-small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial
Immune-modulatory Radiotherapy to Enhance the Effects of Neoadjuvant PD-L1 Blockade After Neoadjuvant Chemotherapy in Patients With Resectable Stage III(N2) Non-small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Radiation, Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Durvalumab, Carboplatin, Paclitaxel
Study Phase: Phase 2
A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Drug, Radiation
Study Drug: Osimertinib
Study Phase: Phase 2
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Enrollment Status: Completed
Publish Date: August 24, 2022
Intervention Type: Drug
Study Phase: Phase 2
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
Enrollment Status: Terminated
Publish Date: April 14, 2022
Intervention Type: Radiation, Drug
Study Drug: Metformin
Study Phase: Phase 2
Radiotherapy and 6-month Androgen Deprivation Therapy With or Without Apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a Phase III Study
Radiotherapy and 6-month Androgen Deprivation Therapy With or Without Apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a Phase III Study
Enrollment Status: Withdrawn
Publish Date: August 17, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial
LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial
Enrollment Status: Unknown
Publish Date: January 31, 2020
Intervention Type: Radiation
Study Phase: Phase 2
View 7 Less Clinical Trials

604 Total Publications

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.
Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.
Journal: JAMA network open
Published: February 03, 2026

Frequently Asked Questions about Matthias Guckenberger

Is Matthias Guckenberger a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Matthias Guckenberger is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Matthias Guckenberger participate in research or clinical trials?

Yes. Matthias Guckenberger has published 604 articles and abstracts on conditions like Lung Cancer. You can view a list of Matthias Guckenberger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guckenberger's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 39 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile